JP2018002724A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018002724A5 JP2018002724A5 JP2017165302A JP2017165302A JP2018002724A5 JP 2018002724 A5 JP2018002724 A5 JP 2018002724A5 JP 2017165302 A JP2017165302 A JP 2017165302A JP 2017165302 A JP2017165302 A JP 2017165302A JP 2018002724 A5 JP2018002724 A5 JP 2018002724A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence represented
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/002211 | 2012-05-23 | ||
| PCT/EP2012/002211 WO2013174404A1 (en) | 2012-05-23 | 2012-05-23 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513043A Division JP6203830B2 (ja) | 2012-05-23 | 2013-05-21 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034057A Division JP6833885B2 (ja) | 2012-05-23 | 2019-02-27 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018002724A JP2018002724A (ja) | 2018-01-11 |
| JP2018002724A5 true JP2018002724A5 (cg-RX-API-DMAC7.html) | 2018-02-22 |
| JP6490763B2 JP6490763B2 (ja) | 2019-03-27 |
Family
ID=48651960
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513043A Active JP6203830B2 (ja) | 2012-05-23 | 2013-05-21 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2017165302A Active JP6490763B2 (ja) | 2012-05-23 | 2017-08-30 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2019034057A Active JP6833885B2 (ja) | 2012-05-23 | 2019-02-27 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2021015688A Active JP7204791B2 (ja) | 2012-05-23 | 2021-02-03 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2022212169A Pending JP2023038230A (ja) | 2012-05-23 | 2022-12-28 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2025023576A Pending JP2025093926A (ja) | 2012-05-23 | 2025-02-17 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015513043A Active JP6203830B2 (ja) | 2012-05-23 | 2013-05-21 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019034057A Active JP6833885B2 (ja) | 2012-05-23 | 2019-02-27 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2021015688A Active JP7204791B2 (ja) | 2012-05-23 | 2021-02-03 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2022212169A Pending JP2023038230A (ja) | 2012-05-23 | 2022-12-28 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
| JP2025023576A Pending JP2025093926A (ja) | 2012-05-23 | 2025-02-17 | がんを処置するためのクローディン１８．２に対する抗体を伴う併用療法 |
Country Status (24)
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| EP2852409B1 (en) | 2012-05-23 | 2020-03-25 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| WO2016165765A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| ES2965437T3 (es) * | 2015-09-03 | 2024-04-15 | Uab Res Found | Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) * | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| JP2020524996A (ja) | 2017-06-16 | 2020-08-27 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| CN107177549A (zh) * | 2017-06-29 | 2017-09-19 | 青岛麦迪赛斯医疗技术有限公司 | 一种简单高效的扩增γδT细胞的方法 |
| JP7381083B2 (ja) * | 2017-09-08 | 2023-11-15 | フォスプラティン テラピューティクス インコーポレイテッド | 免疫調節剤としてのホスファプラチン化合物およびその治療的使用 |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| EP3765522A4 (en) * | 2018-03-14 | 2022-05-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODIES |
| US11059887B2 (en) | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
| JP7513605B2 (ja) * | 2018-07-18 | 2024-07-09 | アスクジーン・ファーマ・インコーポレイテッド | 新規な抗体ならびにそれを調製および使用するための方法 |
| KR20210050547A (ko) * | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-클라우딘18.2 항체 및 이의 용도 |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| JP2022511394A (ja) * | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法 |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| BR112021011014A2 (pt) * | 2018-12-07 | 2021-08-31 | Zlip Holding Limited | Anticorpos anti-claudina e usos destes |
| KR20210110339A (ko) * | 2018-12-28 | 2021-09-07 | 난징 진스크립트 바이오테크 컴퍼니 리미티드 | 클라우딘18.2 결합 모이어티 및 그 용도 |
| EP3902824A4 (en) * | 2018-12-28 | 2023-01-04 | Sparx Therapeutics Inc. | FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES |
| CN119350498A (zh) * | 2018-12-28 | 2025-01-24 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| CN111434692B (zh) * | 2019-01-15 | 2021-12-31 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| WO2020205331A1 (en) * | 2019-03-29 | 2020-10-08 | Phanes Therapeutics, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
| EP3971208A4 (en) * | 2019-05-16 | 2022-11-30 | Qilu Pharmaceutical Co., Ltd. | ANTIBODIES TO CLAUDIN 18A2 AND USE THEREOF |
| CN117659190A (zh) * | 2019-05-16 | 2024-03-08 | 启愈生物技术(上海)有限公司 | 抗cldn抗体及其药物组合物和检测方法 |
| CN114206935B (zh) | 2019-05-24 | 2024-01-12 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| CA3136281C (en) * | 2019-05-30 | 2024-06-25 | Shandong Boan Biotechnology Co., Ltd. | Antibody or chimeric antigen receptor which targets claudin 18.2 |
| WO2021024020A1 (en) * | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| BR112021008870A2 (pt) | 2019-08-12 | 2021-11-30 | Abl Bio Inc | Anticorpo, um ou mais polinucleotídeos, composição, uso do anticorpo, e, método para tratar câncer. |
| US20220332829A1 (en) * | 2019-09-16 | 2022-10-20 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Anti-b7-h3 antibody and application thereof |
| CN112574307B (zh) * | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
| CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
| US20230030674A1 (en) | 2019-12-06 | 2023-02-02 | Sotio Biotech A.S. | Humanized cldn18.2 antibodies |
| CN114761433B (zh) * | 2019-12-11 | 2025-07-29 | 上海复宏汉霖生物技术股份有限公司 | 一种抗Claudin18.2单克隆抗体、其制备方法及用途 |
| WO2021129927A1 (en) | 2019-12-23 | 2021-07-01 | Biontech Cell & Gene Therapies Gmbh | Treatment with immune effector cells engineered to express an antigen receptor |
| WO2021130291A1 (en) | 2019-12-23 | 2021-07-01 | SOTIO a.s. | Tumor-specific claudin 18.2 antibodies |
| CN115715202B (zh) * | 2020-05-15 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 抗体药物缀合物及其制备方法和用途 |
| KR20230042035A (ko) | 2020-07-08 | 2023-03-27 | 라바 테라퓨틱스 엔.브이. | Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체 |
| CN111705085B (zh) * | 2020-08-20 | 2020-12-25 | 北京百奥赛图基因生物技术有限公司 | 构建动物模型的方法及应用 |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| JP2022061640A (ja) * | 2020-10-07 | 2022-04-19 | 株式会社村田製作所 | 積層セラミックコンデンサ |
| WO2022100590A1 (zh) * | 2020-11-10 | 2022-05-19 | 齐鲁制药有限公司 | 针对密蛋白18a2的adcc增强型人源化抗体及其应用 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| TW202241519A (zh) | 2020-12-23 | 2022-11-01 | 捷克商舒迪安生物技術公司 | 腫瘤特異性密連蛋白１８﹒２抗體藥物結合物 |
| AU2022371521A1 (en) * | 2021-10-19 | 2024-05-02 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
| JP2024540062A (ja) * | 2021-11-05 | 2024-10-31 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | 抗ｃｌｄｎ１８．２抗体及びその用途 |
| CN116162168A (zh) | 2021-11-25 | 2023-05-26 | 信达细胞制药(苏州)有限公司 | 分子开关调控型嵌合抗原受体细胞和抗体的组合及其应用 |
| WO2023235808A2 (en) * | 2022-06-01 | 2023-12-07 | Integral Molecular, Inc. | Claudin 18.2 antibodies, methods of making the same, and uses thereof |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| WO2026050214A1 (en) | 2024-08-27 | 2026-03-05 | Bolt Biotherapeutics, Inc. | Anti-claudin, tlr agonist immunoconjugates and uses thereof |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| WO2000078961A1 (en) | 1999-06-23 | 2000-12-28 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| NZ531664A (en) | 1998-09-01 | 2005-07-29 | Genentech Inc | Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family |
| EP1144629A3 (en) | 1998-09-01 | 2001-11-28 | Genentech, Inc. | Further pro polypeptides and sequences thereof |
| CA2343001A1 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| AU766279B2 (en) | 1998-10-06 | 2003-10-16 | Curagen Corporation | Novel secreted proteins and polynucleotides encoding them |
| WO2000058473A2 (en) | 1999-03-31 | 2000-10-05 | Curagen Corporation | Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| CA2380355A1 (en) | 1999-09-01 | 2001-03-08 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6380362B1 (en) | 1999-12-23 | 2002-04-30 | Genesis Research & Development Corporation Ltd. | Polynucleotides, polypeptides expressed by the polynucleotides and methods for their use |
| WO2001055301A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| EP1251863A4 (en) | 2000-01-31 | 2005-03-02 | Human Genome Sciences Inc | 22 HUMAN SECRETED PROTEINS |
| EP1255778A2 (en) | 2000-01-31 | 2002-11-13 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| WO2001055326A2 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
| AU6802801A (en) | 2000-03-01 | 2001-09-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2001260847A1 (en) | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
| ES2284678T3 (es) | 2000-08-15 | 2007-11-16 | Immunex Corporation | Polipeptidos de claudinas. |
| JP2004520814A (ja) | 2000-08-28 | 2004-07-15 | ディアデクサス インコーポレーテッド | 肺特異的遺伝子に関する組成物および方法 |
| ATE549347T1 (de) | 2000-09-08 | 2012-03-15 | Schering Corp | Gene von säugetiere, und damit verbundene reagentien, methoden |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| BRPI0315295C1 (pt) | 2002-10-17 | 2021-05-25 | Genmab As | anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2004063355A2 (en) | 2003-01-10 | 2004-07-29 | Protein Design Labs, Inc. | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer |
| KR20060134216A (ko) * | 2004-04-16 | 2006-12-27 | 에미스페어 테크놀로지스, 인코포레이티드 | 활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염 |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004042822A1 (de) | 2004-08-31 | 2006-03-16 | Technische Universität Dresden | Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen |
| WO2007027867A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1930414B1 (en) * | 2005-09-08 | 2012-07-18 | Medinet Co., Ltd. | Method for activation treatment of antigen-presenting cell |
| EP2402758B1 (en) | 2005-09-19 | 2014-09-10 | Janssen Diagnostics, LLC | Methods and uses for identifying the origin of a carcinoma of unknown primary origin |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| JP5399712B2 (ja) * | 2005-12-21 | 2014-01-29 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 可溶性ｃｅａに対する抵抗性を有する医薬組成物 |
| US20100129929A1 (en) | 2006-07-27 | 2010-05-27 | Roberto Polakewicz | Tyrosine Phosphorylation Sites |
| JP5666136B2 (ja) | 2007-02-01 | 2015-02-12 | ジャンセン ダイアグノスティックス，エルエルシー | 原発不明がんの原発巣を同定するための方法および材料 |
| EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| JPWO2008152822A1 (ja) * | 2007-06-15 | 2010-08-26 | 株式会社メディネット | 医薬 |
| US20090274698A1 (en) | 2007-07-06 | 2009-11-05 | Shripad Bhagwat | Combination anti-cancer therapy |
| EP2036987A1 (en) | 2007-09-17 | 2009-03-18 | Siemens Healthcare Diagnostics GmbH | Molecular markers for tumor cell content in tissue samples |
| MX2010008099A (es) | 2008-01-28 | 2010-08-04 | Medimmune Ltd | Anticuerpos y angiopoyetina-2 estabilizados y sus usos. |
| EP2304053A1 (en) | 2008-06-02 | 2011-04-06 | NSABP Foundation, Inc. | Identification and use of prognostic and predictive markers in cancer treatment |
| EP2316026A1 (en) | 2008-07-25 | 2011-05-04 | Merck Patent GmbH | Method of determination of receptor binding saturation effected by monoclonal antibodies |
| WO2010141093A2 (en) * | 2009-06-04 | 2010-12-09 | The University Of Maryland, Baltimore | Co-signaling methods for treating cancers |
| WO2011090005A1 (ja) * | 2010-01-19 | 2011-07-28 | 協和発酵キリン株式会社 | 大腸癌の治療用医薬および治療方法 |
| US8840902B2 (en) | 2010-03-16 | 2014-09-23 | Biontech Ag | Tumor vaccination involving a humoral immune response against self-proteins |
| CN102168067B (zh) * | 2011-02-11 | 2012-08-29 | 浙江大学 | 一种调节性t细胞的诱导培养方法 |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| JP6241403B2 (ja) | 2014-10-24 | 2017-12-06 | 横浜ゴム株式会社 | リン酸変性ポリマー |
-
2012
- 2012-05-23 WO PCT/EP2012/002211 patent/WO2013174404A1/en not_active Ceased
-
2013
- 2013-05-21 KR KR1020237009833A patent/KR102810919B1/ko active Active
- 2013-05-21 SM SM20220325T patent/SMT202200325T1/it unknown
- 2013-05-21 CN CN201611203370.0A patent/CN107412773B/zh active Active
- 2013-05-21 JP JP2015513043A patent/JP6203830B2/ja active Active
- 2013-05-21 NZ NZ701575A patent/NZ701575A/en unknown
- 2013-05-21 IL IL318824A patent/IL318824A/en unknown
- 2013-05-21 AU AU2013265637A patent/AU2013265637B8/en active Active
- 2013-05-21 SG SG11201406963RA patent/SG11201406963RA/en unknown
- 2013-05-21 LT LTEP20163993.7T patent/LT3725810T/lt unknown
- 2013-05-21 KR KR1020147036039A patent/KR102188001B1/ko active Active
- 2013-05-21 BR BR112014028941A patent/BR112014028941B8/pt active IP Right Grant
- 2013-05-21 KR KR1020257016132A patent/KR20250077600A/ko active Pending
- 2013-05-21 IL IL276434A patent/IL276434B2/en unknown
- 2013-05-21 SG SG10201609510UA patent/SG10201609510UA/en unknown
- 2013-05-21 PT PT201639937T patent/PT3725810T/pt unknown
- 2013-05-21 CN CN201380026898.3A patent/CN104427999B/zh active Active
- 2013-05-21 RS RS20220682A patent/RS63437B1/sr unknown
- 2013-05-21 PL PL20163993.7T patent/PL3725810T3/pl unknown
- 2013-05-21 RU RU2014152107A patent/RU2662066C2/ru active
- 2013-05-21 ES ES13729591T patent/ES2784855T3/es active Active
- 2013-05-21 ES ES20163993T patent/ES2924023T3/es active Active
- 2013-05-21 KR KR1020207034499A patent/KR102514338B1/ko active Active
- 2013-05-21 US US14/401,557 patent/US9433675B2/en active Active
- 2013-05-21 UA UAA201413807A patent/UA115985C2/uk unknown
- 2013-05-21 SI SI201332002T patent/SI3725810T1/sl unknown
- 2013-05-21 HU HUE20163993A patent/HUE059241T2/hu unknown
- 2013-05-21 HK HK15108681.0A patent/HK1208151A1/xx unknown
- 2013-05-21 WO PCT/EP2013/001503 patent/WO2013174509A1/en not_active Ceased
- 2013-05-21 CN CN201611203411.6A patent/CN107050460B/zh active Active
- 2013-05-21 MX MX2014014215A patent/MX367241B/es active IP Right Grant
- 2013-05-21 HR HRP20220897TT patent/HRP20220897T8/hr unknown
- 2013-05-22 AR ARP130101785A patent/AR091131A1/es not_active Application Discontinuation
-
2014
- 2014-11-13 IL IL235672A patent/IL235672B/en active IP Right Grant
- 2014-11-21 MX MX2019009441A patent/MX2019009441A/es unknown
- 2014-11-21 MX MX2020011768A patent/MX2020011768A/es unknown
- 2014-11-21 MX MX2020011796A patent/MX2020011796A/es unknown
- 2014-11-21 MX MX2020011795A patent/MX2020011795A/es unknown
-
2016
- 2016-08-08 US US15/231,185 patent/US10022444B2/en active Active
-
2017
- 2017-08-30 JP JP2017165302A patent/JP6490763B2/ja active Active
-
2018
- 2018-03-15 AU AU2018201856A patent/AU2018201856B2/en active Active
- 2018-05-07 US US15/973,116 patent/US10813996B2/en active Active
-
2019
- 2019-02-27 JP JP2019034057A patent/JP6833885B2/ja active Active
-
2020
- 2020-05-29 AU AU2020203557A patent/AU2020203557A1/en not_active Abandoned
- 2020-08-31 US US17/008,316 patent/US12059464B2/en active Active
-
2021
- 2021-02-03 JP JP2021015688A patent/JP7204791B2/ja active Active
-
2022
- 2022-12-28 JP JP2022212169A patent/JP2023038230A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200682A patent/AU2023200682A1/en active Pending
-
2024
- 2024-06-27 US US18/757,437 patent/US20240335533A1/en active Pending
-
2025
- 2025-02-17 JP JP2025023576A patent/JP2025093926A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018002724A5 (cg-RX-API-DMAC7.html) | ||
| RU2014152107A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| RU2014152115A (ru) | Комбинированная терапия с использованием антител к клаудину 18.2 для лечения рака | |
| ME02932B (me) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
| RU2015139901A (ru) | Комбинированная терапия с использованием антител против клаудина 18.2 для лечения рака | |
| HRP20211346T1 (hr) | Kombinirani pripravci za liječenje raka | |
| JP2020508317A5 (cg-RX-API-DMAC7.html) | ||
| JP2018516966A5 (cg-RX-API-DMAC7.html) | ||
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| JP2019517549A5 (cg-RX-API-DMAC7.html) | ||
| JP2016536314A5 (cg-RX-API-DMAC7.html) | ||
| JP2007535895A5 (cg-RX-API-DMAC7.html) | ||
| RU2016129894A (ru) | Ковалентно связанные конъюгаты хеликар-антитело против хеликара и их применения | |
| JP2018508512A5 (cg-RX-API-DMAC7.html) | ||
| JP2021511372A5 (cg-RX-API-DMAC7.html) | ||
| JP2006265245A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518454A5 (cg-RX-API-DMAC7.html) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2018508483A5 (cg-RX-API-DMAC7.html) | ||
| JP2016520082A5 (cg-RX-API-DMAC7.html) | ||
| JP2022512851A5 (cg-RX-API-DMAC7.html) | ||
| JP2015500822A5 (cg-RX-API-DMAC7.html) | ||
| HRP20221319T1 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| JP2018531994A5 (cg-RX-API-DMAC7.html) | ||
| JP2014500278A5 (cg-RX-API-DMAC7.html) |